Health and Medicine (Audio)

Cognitive resilience depends on how the brain responds to environment, aging, and inflammation. J. Tiago Gonçalves, Ph.D., studies the hippocampus to examine how spatial memory is shaped by factors such as cognitive enrichment, exercise, social interaction, disease, and age. Gonçalves explains how adult neurogenesis and microglia help support the brain’s ability to encode information, and how disruptions in these systems can affect memory. He also shows that aging and systemic inflammation can weaken spatial encoding while still revealing signs of adaptation and recovery over time. By connecting brain plasticity, immune activity, and memory formation, Gonçalves presents a broader view of how cognition changes across the lifespan and how these mechanisms may inform future strategies for addressing cognitive decline Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40848]

Alpha Clinics in California accelerate the development of regenerative medicine therapies that use cells and genes to treat serious diseases. Patient advocate Tara Radcliffe Ghiglieri shares lived experience with gene therapy, while Sheldon Morris, M.D., M.P.H., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Catriona Jamieson, M.D., Ph.D., Michael Lewis, M.D., Mark Walters, M.D., and Leo D. Wang, M.D., Ph.D., describe how Alpha Clinic teams design and deliver clinical trials for a wide range of conditions, including cancer, blood disorders, neurologic disease, osteoarthritis, metabolic disorders, pulmonary arterial hypertension, and Duchenne muscular dystrophy. They highlight how coordinated networks, community partnerships, and genomic tools help expand access, lower financial barriers, and bring promising cell and gene therapies to more patients while carefully tracking safety, effectiveness, and long-term outcomes. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41168]

Off-the-shelf immune cell therapies using engineered T cells represent an important direction in cancer treatment. Lili Yang, Ph.D., at UCLA develops an off-the-shelf platform based on invariant natural killer T (iNKT) cells generated from hematopoietic stem cells, often sourced from cord blood. Yang programs these stem cells with iNKT cell receptors, chimeric antigen receptors (CARs), and genes such as IL-15 to create pure, expandable iNKT products that recognize lipid antigens presented by non polymorphic CD1d molecules. These cells combine multiple killing mechanisms, infiltrate tissues, target tumor cells and immunosuppressive myeloid cells, and show reduced risk of graft versus host disease and cytokine release syndrome in preclinical models. Yang’s group tests this strategy in models of blood cancers and solid tumors, aiming to generate many therapeutic doses from a single donor. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 40846]

How fast are you really aging, and what could that mean for brain health? Aladdin H. Shadyab, Ph.D., explores the gap between chronological age and biological age, and why that difference matters for long-term health. Shadyab describes tools that use information from blood to estimate how quickly the body is aging, including approaches that look beyond the body as a whole to consider aging in specific systems. He connects faster biological aging with higher risk for age-related disease and declines in physical and cognitive function, and discusses how blood-based biomarkers may offer earlier signals of processes linked to Alzheimer’s disease. Shadyab also highlights lifestyle and treatment findings that may support healthier aging and longer survival. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 41073]

RNA binding proteins help cells control how genetic information becomes working proteins, and Gene Yeo, Ph.D., M.B.A., at UC San Diego investigates how their disruption contributes to neurodegenerative disease. Yeo focuses on ALS, a severe motor neuron disease in which the RNA binding protein TDP-43 moves from the nucleus to the cytoplasm, loses normal RNA processing functions, and triggers cryptic exons that damage key neuronal genes, including one linked to motor neuropathy. His group maps these RNA changes and develops small nuclear RNA guides packaged in AAV vectors to block harmful splice sites and restore healthy RNA and protein levels. In cell cultures and a humanized mouse model, this strategy improves axon growth and supports the idea that multiplexed RNA-targeted therapies could correct multiple disease pathways at once. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41166]